Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 704-706

  Kaidar Person, Orit ^a   Billan, Salem ^a   Kuten, Abraham ^a  

^a Division of Oncology   (Israel)

Author keywords

Carcinoma; Ductal carcinoma; HER 2; Human epidermal growth factor receptor 2; Salivary gland; Targeted therapy; Trastuzumab

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER METASTASIS; LYMPH NODE DISSECTION; MALE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; PAROTIDECTOMY; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND CARCINOMA; TREATMENT RESPONSE; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SALIVARY GLAND TUMOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS; TREATMENT OUTCOME;

EID: 84866326620     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9884-1     Document Type: Review

References (15)

1. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.
2. Press MF, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54:5675-82.
3. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006; 24:2673-8.
4. Glisson B, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10: 944-6.
5. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007;29:907-11.
6. Haddad R, Posner MR. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol. 2003;1:226-8.
7. Haddad R, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39:724-7.
8. Cornolti G, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg. 2007;133: 1031-6.
9. Robert N, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786-92.
10. Seifert G, Brocheriou C, Cardesa A, Eveson JW. WHO international histological classification of tumours. Tentative histological classification of salivary gland tumours. Pathol Res Pract. 1990;186:555-81.
11. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol. 2001;12(Suppl 1):S81-7.
12. Skálová A, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2003;42:348-56.
13. Skálová A, Stárek I, Kucerová V, Szépe P, Plank L. Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract. 2001;197: 621-6.
14. Johnson CJ, Barry MB, Vasef MA, Deyoung BR. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol. 2008;16:54-8.
15. Prat A, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008;30:680-3.